Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

Key Terms

cervical cancer screenings medical

Cervical cancer screenings are medical tests performed on people with a cervix to look for abnormal cells or signs of early cancer before symptoms appear, often using cell samples or infection tests. For investors, screening programs shape demand for laboratory services, diagnostics devices, vaccines and follow-up care — like routine maintenance that determines how much business healthcare providers and manufacturers will get and how regulators or insurers may change coverage.

cervical cancer medical

A type of cancer that starts in the cervix, the narrow lower part of the uterus, typically developing when abnormal cells grow uncontrollably. It matters to investors because prevention, screening, diagnostic tests, drugs and surgical treatments create markets and revenue streams for vaccine makers, device companies, drug developers, hospitals and insurers; changes in incidence, screening guidelines, clinical trial results or regulatory decisions can materially affect those companies’ financial outlooks, much like discovering a structural problem can reshape the costs and plans for a building.

gynecology medical

Gynecology is the branch of medicine focused on the health, diagnosis and treatment of the female reproductive system, including organs, hormonal function and related preventive care. For investors, gynecology matters because demand for related services, drugs, devices and screenings drives revenue and regulatory risk in healthcare businesses—think of it as routine maintenance and upgrades for an essential part of a population’s health that influences patient volumes, product sales and long‑term costs.

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $88,000 from distribution partner Hangzhou Dongye Medical Technology Company Ltd (HDMT). Eighty thousand dollars of this payment is the third installment of a $700,000 purchase order the Company received from HDMT earlier this year and the additional $8,000 is a new order for LuViva components. The four LuViva devices and components will be shipped this month and will bring the total number of devices shipped to seven of the 35 devices due over the next several months. HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually.

The purchase order with HDMT was recently complemented by a new agreement with Yuanshuo Medical Instruments Corporation (YMIC) for an initial $200,000 purchase of LuViva devices and parts. YMIC is headquartered in Jiangsu province where it will distribute LuViva products.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251211649678/en/

Mark Faupel

Guided Therapeutics

770-242-8723

Source: Guided Therapeutics, Inc.